384 related articles for article (PubMed ID: 8001943)
1. Risk factors for hepatitis C virus infection among injecting drug users in Sydney.
van Beek I; Buckley R; Stewart M; MacDonald M; Kaldor J
Genitourin Med; 1994 Oct; 70(5):321-4. PubMed ID: 8001943
[TBL] [Abstract][Full Text] [Related]
2. High hepatitis C incidence in new injecting drug users: a policy failure?
Maher L; Li J; Jalaludin B; Chant KG; Kaldor JM
Aust N Z J Public Health; 2007 Feb; 31(1):30-5. PubMed ID: 17333606
[TBL] [Abstract][Full Text] [Related]
3. Risk behaviors and antibody hepatitis B and C prevalence among injecting drug users in south-western Sydney, Australia.
Maher L; Chant K; Jalaludin B; Sargent P
J Gastroenterol Hepatol; 2004 Oct; 19(10):1114-20. PubMed ID: 15377287
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C and HIV incidence and harm reduction program use in a conflict setting: an observational cohort of injecting drug users in Kabul, Afghanistan.
Todd CS; Nasir A; Stanekzai MR; Fiekert K; Sipsma HL; Vlahov D; Strathdee SA
Harm Reduct J; 2015 Oct; 12():22. PubMed ID: 26472126
[TBL] [Abstract][Full Text] [Related]
5. HIV infection and risk, prevention, and testing behaviors among injecting drug users -- National HIV Behavioral Surveillance System, 20 U.S. cities, 2009.
Broz D; Wejnert C; Pham HT; DiNenno E; Heffelfinger JD; Cribbin M; Krishna N; Teshale EH; Paz-Bailey G;
MMWR Surveill Summ; 2014 Jul; 63(6):1-51. PubMed ID: 24990587
[TBL] [Abstract][Full Text] [Related]
6. HIV and hepatitis C virus risk in new and longer-term injecting drug users in Oslo, Norway.
Miller M; Mella I; Moi H; Eskild A
J Acquir Immune Defic Syndr; 2003 Jul; 33(3):373-9. PubMed ID: 12843749
[TBL] [Abstract][Full Text] [Related]
7. Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study.
van Beek I; Dwyer R; Dore GJ; Luo K; Kaldor JM
BMJ; 1998 Aug; 317(7156):433-7. PubMed ID: 9703523
[TBL] [Abstract][Full Text] [Related]
8. Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales.
Sutton AJ; Gay NJ; Edmunds WJ; Hope VD; Gill ON; Hickman M
BMC Infect Dis; 2006 Jun; 6():93. PubMed ID: 16762050
[TBL] [Abstract][Full Text] [Related]
9. Blood-borne virus infections among Australian injecting drug users: implications for spread of HIV.
Crofts N; Hopper JL; Milner R; Breschkin AM; Bowden DS; Locarnini SA
Eur J Epidemiol; 1994 Dec; 10(6):687-94. PubMed ID: 7672048
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C virus infection, HIV co-infection, and associated risk among injecting drug users in Togliatti, Russia.
Rhodes T; Platt L; Judd A; Mikhailova LA; Sarang A; Wallis N; Alpatova T; Hickman M; Parry JV
Int J STD AIDS; 2005 Nov; 16(11):749-54. PubMed ID: 16303071
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C virus infection among a cohort of Victorian injecting drug users.
Crofts N; Hopper JL; Bowden DS; Breschkin AM; Milner R; Locarnini SA
Med J Aust; 1993 Aug; 159(4):237-41. PubMed ID: 7692222
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C virus antibody prevalence among injecting drug users in Glasgow has fallen but remains high.
Goldberg D; Cameron S; McMenamin J
Commun Dis Public Health; 1998 Jun; 1(2):95-7. PubMed ID: 9644121
[TBL] [Abstract][Full Text] [Related]
13. Male IDUs who have sex with men in England, Wales and Northern Ireland: are they at greater risk of bloodborne virus infection and harm than those who only have sex with women?
Marongiu A; Hope VD; Parry JV; Ncube F
Sex Transm Infect; 2012 Oct; 88(6):456-61. PubMed ID: 22628667
[TBL] [Abstract][Full Text] [Related]
14. Co-infection by human immuno deficiency virus, hepatitis B and hepatitis C virus in injecting drug users.
Devi KhS; Brajachand N; Singh HL; Singh YM
J Commun Dis; 2005 Mar; 37(1):73-7. PubMed ID: 16637404
[TBL] [Abstract][Full Text] [Related]
15. Alarming epidemics of human immunodeficiency virus and hepatitis C virus among injection drug users in the northwestern bordering state of Punjab, India: prevalence and correlates.
Panda S; Roy T; Pahari S; Mehraa J; Sharma N; Singh G; Singh J; Joseph F; Singh S; Sharma NM
Int J STD AIDS; 2014 Jul; 25(8):596-606. PubMed ID: 24352120
[TBL] [Abstract][Full Text] [Related]
16. Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection.
Patrick DM; Tyndall MW; Cornelisse PG; Li K; Sherlock CH; Rekart ML; Strathdee SA; Currie SL; Schechter MT; O'Shaughnessy MV
CMAJ; 2001 Oct; 165(7):889-95. PubMed ID: 11599327
[TBL] [Abstract][Full Text] [Related]
17. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence.
Turner KM; Hutchinson S; Vickerman P; Hope V; Craine N; Palmateer N; May M; Taylor A; De Angelis D; Cameron S; Parry J; Lyons M; Goldberg D; Allen E; Hickman M
Addiction; 2011 Nov; 106(11):1978-88. PubMed ID: 21615585
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of HIV, hepatitis B and hepatitis C and associated risk behaviours amongst injecting drug users in three Afghan cities.
Nasir A; Todd CS; Stanekzai MR; Bautista CT; Botros BA; Scott PT; Strathdee SA; Tjaden J
Int J Drug Policy; 2011 Mar; 22(2):145-52. PubMed ID: 21146392
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis C prevalence and risk behavior of injecting drug users in Sydney: a continuing concern.
Habib SE; Lovejoy FH; Aspin C
Southeast Asian J Trop Med Public Health; 2001 Dec; 32(4):823-34. PubMed ID: 12041560
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C virus acquisition among injecting drug users: a cohort analysis of a national repeated cross-sectional survey of needle and syringe program attendees in Australia, 1995-2004.
Falster K; Kaldor JM; Maher L;
J Urban Health; 2009 Jan; 86(1):106-18. PubMed ID: 18979201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]